BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gherardi A, Roze S, Kuijvenhoven J, Ghatnekar O, Yip Sonderegger YL. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. J Med Econ 2018;21:869-77. [PMID: 29857775 DOI: 10.1080/13696998.2018.1484371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Greenberg S, Herfarth HH, Barnes EL. Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:115-22. [PMID: 31559263 DOI: 10.1159/000501004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]